# First-In-Human (FIH), Single Ascending Dose (SAD) Study of FluoroEthylNorMemantine (FENM)

> **NCT05921929** · PHASE1 · WITHDRAWN · sponsor: **ReST Therapeutics**

## Conditions studied

- PTSD
- Alzheimer Disease
- Brain Diseases
- Neuro-Degenerative Disease
- Major Depressive Disorder
- Treatment Resistant Depression

## Interventions

- **DRUG:** Fluoroethylnormemantine (FENM)

## Key facts

- **NCT ID:** NCT05921929
- **Lead sponsor:** ReST Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-05-02
- **Primary completion:** 2024-05-02
- **Final completion:** 2024-05-02
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** a new trial should be designed
- **Last updated:** 2024-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05921929

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05921929, "First-In-Human (FIH), Single Ascending Dose (SAD) Study of FluoroEthylNorMemantine (FENM)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05921929. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*